Gomes, Luis Aragão
Hipp, Silvia Andrea
Rijal Upadhaya, Ajeet
Balakrishnan, Karthikeyan
Ospitalieri, Simona
Koper, Marta J.
Largo-Barrientos, Pablo
Uytterhoeven, Valerie
Reichwald, Julia
Rabe, Sabine
Vandenberghe, Rik
von Arnim, Christine A. F.
Tousseyn, Thomas
Feederle, Regina
Giudici, Camilla
Willem, Michael
Staufenbiel, Matthias
Thal, Dietmar Rudolf http://orcid.org/0000-0002-1036-1075
Funding for this research was provided by:
Fonds Wetenschappelijk Onderzoek (G0F8516N)
Alzheimer Forschung Initiative (#10810)
Vlaamse Overheid (IWT 135043)
Article History
Received: 8 January 2019
Revised: 26 July 2019
Accepted: 31 July 2019
First Online: 14 August 2019
Compliance with ethical standards
:
: DRT received consultant honorary from GE-Healthcare (UK), and Covance Laboratories (UK), speaker honorary from Novartis Pharma AG (Switzerland), travel reimbursement from GE-Healthcare (UK), and UCB (Belgium), and collaborated with Novartis Pharma AG (Switzerland), Probiodrug (Germany), GE-Healthcare (UK), and Janssen Pharmaceutical Companies (Belgium). JR and MS were employees of Novartis Pharma Basel and SR is employee of Novartis Pharma Basel (Switzerland). CAFvA received honoraria from serving on the scientific advisory board of Nutricia GmbH (2014), Roche (2018) and Honkong University Research Council (2014) and has received funding for travel and speaker honoraria from Nutricia GmbH (2014–2015), Lilly Deutschland GmbH (2013–2016), Desitin Arzneimittel GmbH (2014), Biogen (2016–2018), Roche (2017–2018), and Dr. Willmar Schwabe GmbH&Co. KG (2014–2015).